The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Research Funding - Celgene; Janssen; Takeda
Bortezomib, lenalidomide, and dexamethasone (VRd) ± daratumumab (DARA) in patients (pts) with newly diagnosed multiple myeloma (NDMM) for whom transplant is not planned as initial therapy: A multicenter, randomized, phase III study (CEPHEUS).
 
Sonja Zweegman
No Relationships to Disclose
 
Saad Zafar Usmani
Consulting or Advisory Role - Abbvie; Amgen; Celgene; GlaxoSmithKline; Janssen Oncology; Karyopharm Therapeutics; Seagen; Takeda
Speakers' Bureau - Amgen; Celgene; Janssen Oncology; Takeda
Research Funding - Amgen; Array BioPharma; Bristol-Myers Squibb; Celgene; Janssen Oncology; Pharmacyclics; Sanofi; Seagen
 
Katherine Chastain
Employment - Janssen
 
Jodi Carey
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Johnson & Johnson
 
Karen Ren
Employment - Janssen
 
Elena Smith
Employment - Janssen
 
Maria Krevvata
Employment - Janssen
 
Jianping Wang
Employment - Janssen
 
Jessica Vermeulen
Employment - Janssen
Stock and Other Ownership Interests - Janssen
 
Thierry Facon
Consulting or Advisory Role - Amgen; Celgene; Janssen; Karyopharm Therapeutics; Oncopeptides; Sanofi; Takeda
Speakers' Bureau - celgene; Janssen; Takeda